Job Trends
The board strongly believes that Walmsley is the correct leader for the pharmaceutical business arm of GSK, which is being referred to as New GSK.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Of the 25 companies receiving tax incentives in Massachusetts, 23 will add jobs outside of Boston and Cambridge. Medtronic, which is receiving the largest award, will create 220 roles in Billerica. Other recipients include AbbVie, Dyne Therapeutics and Viridian Therapeutics.
Looking for a job in regulatory? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Looking for a job in oncology? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
THE LATEST
The two posters outlining ongoing formulation efforts to develop a trivalent thermostabilized Ebola vaccine presented on Wednesday July 31 at the 2019 Colorado Protein Stability Conference are now available.
Device Also Can Serve as Robotic Skin, Relaying Information Back to the User
Neos Therapeutics, Inc. announced that it will report its second quarter 2019 financial results prior to the opening of U.S. financial markets on Thursday, August 8, 2019.
Novartis announced that its Phase III MONALEESA-3 clinical trial of Kisqali (ribociclib) hit its key secondary endpoint, overall survival, in a pre-planned interim analysis.
University of Houston Researchers Report Adaptable Stimulation Treatment
FGFR inhibitor gains FDA approval based on 40% response rate in MD Anderson-led Phase II trial
“Our ultimate goal is to provide a solution to an organ shortage that causes an average of 20 people per day in the U.S. alone to die waiting for an organ transplant,” quoted Rich Boling, the vice-president of corporate advancement at Techshot.
This week has marked a number of stories over construction projects and real estate developers focused on the life sciences market. Here’s a look.
Study reports pre-clinical development of novel treatment and potential for combination use with immunotherapy drugs
In a deal-making spree, Genentech will team up with the small companies to take on various diseases, including multiple sclerosis.